The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022Assessing Genetic Predisposition to Gastrointestinal Symptoms in Young-onset and Late-onset Parkinson’s Disease
Study Rationale: Constipation is a common, nonmotor manifestation of Parkinson’s disease (PD) that can impact the quality of life of people with the condition. Yet little is known about the genetic...
-
Research Grant, 2022Evaluation of a Monitoring System Based on a Wearable Sensor for Improving Swallowing and Saliva Control in Parkinson’s Disease
Study Rationale: Trouble with swallowing and increased drooling are common issues for people with Parkinson’s disease (PD). These oral symptoms occur in up to 80% of cases. Our prior work showed that...
-
Summer 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022Assessing Whether Cholesterol or Its Metabolites Increase the Risk of Developing Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) has been associated with a dysregulation of cholesterol metabolism in brain cells and the accumulation of a protein called alpha-synuclein. Our research is...
-
Research Grant, 2022Performing a First-In-Human Study of a Retinal Tracer For Alpha-synuclein in Parkinson's Disease
Study Rationale: Like the brain, the retina is part of the central nervous system. We therefore aim to develop a new and simple way to diagnose Parkinson’s disease (PD) via examination of the eye. To...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Developing an Inhibitor of Transglutaminase 2 as a Disease-modifying Treatment for Parkinson’s Disease
Study Rationale: Clumping of alpha-synuclein in the brain is a key pathological feature of Parkinson’s disease (PD) and is believed to lead to brain cell degeneration. Identifying factors that...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Evaluating an Insulin-degrading Enzyme as a Novel Therapeutic Target for Parkinson’s Disease
Study Rationale: In Parkinson’s disease (PD), the clumping of the protein alpha-synuclein in the brain causes the death of neurons. Recent studies have shown that the insulin-degrading enzyme (IDE)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.